Cargando…
Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth
The development of short interfering RNA (siRNA), has provided great hope for therapeutic targeting of specific genes responsible for patholological disorders. However, the poor cellular uptake and bioavailability of siRNA remain a major obstacle to their clinical development and most strategies tha...
Autores principales: | Crombez, Laurence, Morris, May Catherine, Dufort, Sandrine, Aldrian-Herrada, Gudrun, Nguyen, Quan, Mc Master, Gary, Coll, Jean-Luc, Heitz, Frederic, Divita, Gilles |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724276/ https://www.ncbi.nlm.nih.gov/pubmed/19483097 http://dx.doi.org/10.1093/nar/gkp451 |
Ejemplares similares
-
A non-covalent peptide-based carrier for in vivo delivery of DNA mimics
por: Morris, May C., et al.
Publicado: (2007) -
Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB–siRNA conjugates
por: Cuellar, Trinna L., et al.
Publicado: (2015) -
Inhibition of MDR1 expression with altritol-modified siRNAs
por: Fisher, Michael, et al.
Publicado: (2007) -
Competition for RISC binding predicts in vitro potency of siRNA
por: Koller, Erich, et al.
Publicado: (2006) -
Live cell imaging of duplex siRNA intracellular trafficking
por: Hirsch, Markus, et al.
Publicado: (2015)